<DOC>
	<DOC>NCT02494206</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.</brief_summary>
	<brief_title>Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Women 1870 with unilateral stage I or II BCRL Volume difference of at least 300 mL between the normal and lymphedematous limb based on perometry evaluation BMI of 1830 No current evidence of breast cancer At least 6 months postop from axillary lymph node dissection Bilateral lymphedema or history of bilateral axillary lymph node dissection Recent history of cellulitis in the affected extremity (within last 3 months) Recurrent breast cancer or other malignancy Current (within last month) use of chemotherapy for breast or other malignancy Current (within last 3 months) use of radiation for breast or other malignancy Recent (within last month) or current intensive MLD and/or short stretch bandage use Unstable lymphedema (i.e. worsening symptoms/measurements in the past 3 months) Pregnant or nursing (lactating) women Stage III lymphedema Patients that take acetaminophen (paracetamol) chronically, i.e. more than 1 g/day for more than 3 out of 7 days, or more than 2 g/ day for more than 1 day out of 7 days Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. monoclonal antibodies, polyclonal gamma globulin, polysorbates).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>QBX258</keyword>
	<keyword>human monoclonal antibodies</keyword>
	<keyword>VAK694</keyword>
	<keyword>QAX576</keyword>
	<keyword>15-085</keyword>
</DOC>